Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.67 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.67 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.67 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.67 |
| ▸ | MAPT | P10636 | 11/20 | 0.59 |
| ▸ | MEN1 | O00255 | 7/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.59 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | TTR | P02766 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23482777 | 0.86 | PIK3CD (0.60) | PIK3CDPIK3CAPIK3CBPIK3CGMAPT | |
| SCHEMBL6764894 | 0.84 | KMT2A (0.77) | MAPTMEN1KMT2AKDM4EPKM | |
| SCHEMBL1792162 | 0.82 | MAPT (0.64) | PIK3CDPIK3CAPIK3CBPIK3CGMAPT | |
| SCHEMBL1792573 | 0.81 | MAPT (0.60) | PIK3CDPIK3CAPIK3CBPIK3CGMAPT | |
| SCHEMBL1793276 | 0.81 | MAPT (0.60) | PIK3CDPIK3CAPIK3CBPIK3CGMAPT | |
| SCHEMBL1788935 | 0.80 | MAPT (0.61) | PIK3CDPIK3CAPIK3CBPIK3CGMAPT | |
| SCHEMBL1793899 | 0.80 | MAPT (0.61) | PIK3CDPIK3CAPIK3CBPIK3CGMAPT | |
| SCHEMBL1792641 | 0.80 | PIK3CD (1.00) | PIK3CDPIK3CAPIK3CBPIK3CGMAPT | |
| SCHEMBL13452267 | 0.78 | MAPT (0.78) | PIK3CDPIK3CAPIK3CBPIK3CGMAPT | |
| SCHEMBL1791652 | 0.78 | TTR (0.81) | PIK3CDPIK3CAPIK3CBPIK3CGMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230372499-A1 | DENDRIMER COMPOSITIONS AND METHODS FOR DRUG DELIVERY | THE JOHNS HOPKINS UNIVERSITY | 2023-11-23 | — | — | US | disclosed |
| US-20230372499-A1 | DENDRIMER COMPOSITIONS AND METHODS FOR DRUG DELIVERY | THE JOHNS HOPKINS UNIVERSITY | 2023-11-23 | — | — | US | disclosed |
| US-20230233696-A1 | TRIANTENNARY N-ACETYLGALACTOSAMINE MODIFIED HYDROXYL POLYAMIDOAMINE DENDRIMERS AND METHODS OF USE THEREOF | Ashvattha Therapeutics, Inc. (US) | 2023-07-27 | — | — | US | disclosed |
| US-20230226199-A1 | DENDRIMER COMPOSITIONS AND METHODS FOR DRUG DELIVERY | Ashvattha Therapeutics, Inc. (US) | 2023-07-20 | — | — | US | disclosed |
| US-20230226199-A1 | DENDRIMER COMPOSITIONS AND METHODS FOR DRUG DELIVERY | Ashvattha Therapeutics, Inc. (US) | 2023-07-20 | — | — | US | disclosed |
| US-20210170040-A1 | DENDRIMER COMPOSITIONS AND METHODS FOR DRUG DELIVERY | PROGRAMMABLE MEDICINE OPERATING COMPANY | 2021-06-10 | — | — | US | disclosed |
| US-9931313-B2 | Methods of treating proliferative disorders with malate or derivatives thereof | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2018-04-03 | — | — | US | disclosed |
| US-9539323-B2 | Methods and compositions for malic enzyme 2 (ME2) as a target for cancer therapy | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2017-01-10 | — | — | US | disclosed |
| US-20150056215-A1 | METHODS OF TREATING PROLIFERATIVE DISORDERS WITH MALATE OR DERIVATIVES THEREOF | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2015-02-26 | — | — | US | disclosed |
| WO-2013152193-A2 | METHODS OF TREATING PROLIFERATIVE DISORDERS WITH MALATE OR DERIVATIVES THEREOF | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2013-10-10 | — | — | WO | disclosed |
| US-20130209488-A1 | METHODS AND COMPOSITIONS FOR MALIC ENZYME 2 (ME2) AS A TARGET FOR CANCER THERAPY | BETH ISRAEL DEACONESS MEDICAL CENTER, INC (US) | 2013-08-15 | — | — | US | disclosed |
| WO-2012019154-A2 | METHODS AND COMPOSITIONS FOR MALIC ENZYME 2 (ME2) AS A TARGET FOR CANCER THERAPY | BETH ISRAEL DEACONESS MEDICAL CENTER (US) | 2012-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230372499-A1 | DENDRIMER COMPOSITIONS AND METHODS FOR DRUG DELIVERY | TIE1, FLT3, FLT1 | PIK3CD 157/4885PIK3CA 38/4885PIK3CB 230/4885 |
| US-20150056215-A1 | METHODS OF TREATING PROLIFERATIVE DISORDERS WITH MALATE OR DERIVATIVES THEREOF | MDH2, MDH1, ME1 | PIK3CD 1428/4885PIK3CA 560/4885PIK3CB 843/4885 |
| US-20230233696-A1 | TRIANTENNARY N-ACETYLGALACTOSAMINE MODIFIED HYDROXYL POLYAMIDOAMINE DENDRIMERS AND METHODS OF USE THEREOF | FUT6, FUT5, OGT | PIK3CD 3560/4885PIK3CA 3737/4885PIK3CB 3393/4885 |
| US-20230226199-A1 | DENDRIMER COMPOSITIONS AND METHODS FOR DRUG DELIVERY | TIE1, FLT3, FLT1 | PIK3CD 157/4885PIK3CA 38/4885PIK3CB 230/4885 |
| US-20210170040-A1 | DENDRIMER COMPOSITIONS AND METHODS FOR DRUG DELIVERY | TIE1, FLT3, FLT1 | PIK3CD 157/4885PIK3CA 38/4885PIK3CB 230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.